Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RDY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RDY and 80,000+ other tickers.
See exactly how RDY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RDY and 80,000+ other tickers.
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services…
Dr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call Transcript
Dr. Reddy's Laboratories NYSE: RDY reported a year-over-year revenue decline and sharply lower profitability for the first quarter of fiscal 2027, as lower lenalidomide sales and semaglutide API-related challenges weighed on results. Management said the company's base business, excluding lenalidomide, continued to grow at a double-digit rate across key geographies.
Indian drugmaker Dr Reddy's reported a smaller-than-expected quarterly profit on Wednesday, as muted sales of a key generic oncology drug and pricing pressure weighed on the competitive U.S. market.
Bessemer Group Inc. boosted its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 28.4% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,823,285 shares of the company's stock after buying an additional 403,219 shares during the period. Bessemer Group
Dr. Reddy's Laboratories NYSE: RDY said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety concerns.